159 related articles for article (PubMed ID: 8126765)
1. A comparison of the actions of platelet activating factor (PAF) antagonists WEB 2170 and WEB 2086 in the horse.
Foster AP; Cunningham FM; Andrews MJ; Lees P
J Vet Pharmacol Ther; 1993 Dec; 16(4):477-87. PubMed ID: 8126765
[TBL] [Abstract][Full Text] [Related]
2. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse.
Foster AP; Lees P; Andrews MJ; Cunningham FM
Equine Vet J; 1992 May; 24(3):203-7. PubMed ID: 1318830
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man.
Hayes JP; Ridge SM; Griffith S; Barnes PJ; Chung KF
J Allergy Clin Immunol; 1991 Jul; 88(1):83-8. PubMed ID: 2071787
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
[TBL] [Abstract][Full Text] [Related]
6. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
Ammit AJ; O'Neill C
Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
da Silva MB; Herion F; Raskinet R; David JL; Gustin P; Dessy C; Lekeux P
Zentralbl Veterinarmed A; 1996 Sep; 43(7):399-413. PubMed ID: 8921726
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of Web 2086 (Paf antagonist) and ketoprofen (Nsaid) on Paf-induced ex vivo platelet aggregation in bovine.
Bastos da Silva M; Herion F; Raskinet R; David JL; Gustin P; Lekeux P
Zentralbl Veterinarmed A; 1997 Apr; 44(2):65-71. PubMed ID: 9284631
[TBL] [Abstract][Full Text] [Related]
9. Effect of a Paf antagonist, WEB 2086, on airway microvascular leakage in the guinea-pig and platelet aggregation in man.
Evans TW; Dent G; Rogers DF; Aursudkij B; Chung KF; Barnes PJ
Br J Pharmacol; 1988 May; 94(1):164-8. PubMed ID: 3401633
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
11. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
Koike H; Imanishi N; Natsume Y; Morooka S
Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
[TBL] [Abstract][Full Text] [Related]
12. The effect of intravenous administration of WEB 2086 on PAF-induced platelet aggregation in healthy Friesian calves.
Bastos da Silva MB; Gustin P; Herion F; Raskinet R; David JL; Gougnard T; Plomteux G; Desmecht D; Lekeux P
Vet Res Commun; 1997 Oct; 21(7):521-31. PubMed ID: 9345719
[TBL] [Abstract][Full Text] [Related]
13. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
14. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory effects of platelet activating factor (PAF) in equine skin.
Foster AP; Cunningham FM; Lees P
Equine Vet J; 1992 May; 24(3):208-14. PubMed ID: 1606934
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
[TBL] [Abstract][Full Text] [Related]
17. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
18. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
